Altargo

RSS

Withdrawn

This medicine's authorisation has been withdrawn

retapamulin
MedicineHumanWithdrawn

Czech is available via eTranslation, the European Commission's machine translation service.

Translate to Czech | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 25 February 2019 the European Commission withdrew the marketing authorisation for Altargo (retapamulin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Glaxo Group Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Altargo was granted marketing authorisation in the EU on 24 May 2007 for the short treatment of some superficial skin infections in adults and children from the age of 9 months. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2012. 

The European Public Assessment Report (EPAR) for Altargo is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (1.12 MB - PDF)

Zobrazit

español (ES) (505.45 KB - PDF)

Zobrazit

čeština (CS) (650.52 KB - PDF)

Zobrazit

dansk (DA) (504.78 KB - PDF)

Zobrazit

Deutsch (DE) (506.21 KB - PDF)

Zobrazit

eesti (ET) (504.17 KB - PDF)

Zobrazit

ελληνικά (EL) (676.26 KB - PDF)

Zobrazit

français (FR) (506.58 KB - PDF)

Zobrazit

italiano (IT) (505.1 KB - PDF)

Zobrazit

latviešu (LV) (651.97 KB - PDF)

Zobrazit

lietuvių (LT) (619.1 KB - PDF)

Zobrazit

magyar (HU) (639.94 KB - PDF)

Zobrazit

Malti (MT) (650.13 KB - PDF)

Zobrazit

Nederlands (NL) (505.72 KB - PDF)

Zobrazit

polski (PL) (654.82 KB - PDF)

Zobrazit

português (PT) (505.57 KB - PDF)

Zobrazit

română (RO) (614.22 KB - PDF)

Zobrazit

slovenčina (SK) (644.28 KB - PDF)

Zobrazit

slovenščina (SL) (635.63 KB - PDF)

Zobrazit

suomi (FI) (504.95 KB - PDF)

Zobrazit

svenska (SV) (504.61 KB - PDF)

Zobrazit

Product information

български (BG) (1.42 MB - PDF)

Zobrazit

español (ES) (812.94 KB - PDF)

Zobrazit

čeština (CS) (1.28 MB - PDF)

Zobrazit

dansk (DA) (815.41 KB - PDF)

Zobrazit

Deutsch (DE) (809.14 KB - PDF)

Zobrazit

eesti (ET) (750.21 KB - PDF)

Zobrazit

ελληνικά (EL) (1.46 MB - PDF)

Zobrazit

français (FR) (815.25 KB - PDF)

Zobrazit

hrvatski (HR) (874.78 KB - PDF)

Zobrazit

italiano (IT) (800.77 KB - PDF)

Zobrazit

latviešu (LV) (1.23 MB - PDF)

Zobrazit

lietuvių (LT) (851.86 KB - PDF)

Zobrazit

magyar (HU) (1.23 MB - PDF)

Zobrazit

Malti (MT) (1.24 MB - PDF)

Zobrazit

Nederlands (NL) (813.69 KB - PDF)

Zobrazit

polski (PL) (1.2 MB - PDF)

Zobrazit

português (PT) (846.48 KB - PDF)

Zobrazit

română (RO) (881.66 KB - PDF)

Zobrazit

slovenčina (SK) (1.22 MB - PDF)

Zobrazit

slovenščina (SL) (1.18 MB - PDF)

Zobrazit

suomi (FI) (806.83 KB - PDF)

Zobrazit

svenska (SV) (780.46 KB - PDF)

Zobrazit

Íslenska (IS) (794.04 KB - PDF)

Zobrazit

norsk (NO) (805.77 KB - PDF)

Zobrazit
Latest procedure affecting product information:N/0030
09/11/2015
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (550.48 KB - PDF)

Zobrazit

español (ES) (468.17 KB - PDF)

Zobrazit

čeština (CS) (543.17 KB - PDF)

Zobrazit

dansk (DA) (463.61 KB - PDF)

Zobrazit

Deutsch (DE) (463.97 KB - PDF)

Zobrazit

eesti (ET) (464.73 KB - PDF)

Zobrazit

ελληνικά (EL) (542.82 KB - PDF)

Zobrazit

français (FR) (464.58 KB - PDF)

Zobrazit

italiano (IT) (463.94 KB - PDF)

Zobrazit

latviešu (LV) (543.45 KB - PDF)

Zobrazit

lietuvių (LT) (528.34 KB - PDF)

Zobrazit

magyar (HU) (541.04 KB - PDF)

Zobrazit

Malti (MT) (541.98 KB - PDF)

Zobrazit

Nederlands (NL) (464.13 KB - PDF)

Zobrazit

polski (PL) (544.12 KB - PDF)

Zobrazit

português (PT) (464.65 KB - PDF)

Zobrazit

română (RO) (524.19 KB - PDF)

Zobrazit

slovenčina (SK) (543.19 KB - PDF)

Zobrazit

slovenščina (SL) (509.38 KB - PDF)

Zobrazit

suomi (FI) (463.61 KB - PDF)

Zobrazit

svenska (SV) (464.71 KB - PDF)

Zobrazit

Product details

Name of medicine
Altargo
Active substance
retapamulin
International non-proprietary name (INN) or common name
retapamulin
Therapeutic area (MeSH)
  • Impetigo
  • Staphylococcal Skin Infections
Anatomical therapeutic chemical (ATC) code
D06AX13

Pharmacotherapeutic group

Antibiotics and chemotherapeutics for dermatological use

Therapeutic indication

Short term treatment of the following superficial skin infections:

  • impetigo;
  • infected small lacerations, abrasions or sutured wounds.

See sections 4.4 and 5.1 for important information regarding the clinical activity of retapamulin against different types of Staphylococcus aureus.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Authorisation details

EMA product number
EMEA/H/C/000757
Marketing authorisation holder
Glaxo Group Ltd

980 Great West Road
Brentford
Middlesex TW8 9GS
United Kingdom

Marketing authorisation issued
24/05/2007
Withdrawal of marketing authorisation
25/02/2019
Revision
15

Assessment history

This page was last updated on

Share this page